Rivian renegotiates DOE loan down to $4.5 billion, adjusts capacity plans for Georgia plant

Rivian renegotiates DOE loan down to .5 billion, adjusts capacity plans for Georgia plant


Watch CNBC's full interview with Rivian CEO RJ Scaringe on the company's Q1 results

Rivian Automotive on Thursday said it has renegotiated a $6.57 billion loan from the U.S. Department of Energy down to $4.5 billion and is adjusting its production expectations at an under-construction plant in Georgia.

The DOE loan was previously set to support two phases of production for a total of 400,000 units annually. The amended loan covers one phase of production with a total capacity of 300,000 vehicles, the company said Thursday.

The changes allow Rivian to draw on the loan sooner and have greater initial production but lowers its total production capacity for the plant amid uncertain demand for all-electric vehicles.

The initial loan terms were negotiated under the Biden administration. It had been in limbo under the Trump administration, which has taken action to cut or reduce such loans and has pulled back government investments to promote EVs.

Rivian said it plans to tap into the loan in 2027, a year ahead of previously scheduled. The automaker also said production of the company’s upcoming R2 electric vehicle is on track to begin at the facility in late 2028, following its recent start to production at its current facility in Normal, Illinois.

Rivian CEO RJ Scaringe on Thursday told CNBC’s Phil LeBeau that any future expansion of the Georgia plant would be funded by the company, which has been raising needed capital through partnerships with companies such as Volkswagen and Uber.

The EV maker announced the new loan details in connection with its first-quarter results, which included a net loss of $416 million, or 33 cents per share, down from a loss of $541 million, or 48 cents per share, a year ago. Those per-share results were not comparable to Wall Street expectations.

Rivian’s revenue for the quarter was $1.38 billion, up from $1.24 billion a year earlier and slightly ahead of the $1.36 billion expected by analysts, according to LSEG.

The company’s gross profit, which is closely watched by investors, was $119 million — down $87 million during the first quarter compared to a year earlier. That included a $62 million loss for its automotive segment and a $181 million profit for its software and services division.

The decline in automotive profit was primarily due to a $100 million slump in sales of automotive regulatory credits and lower production volumes, Rivian said.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.



Source

Pricey NFL, NBA ownership stakes are pushing investors to smaller leagues and driving valuations higher
Business

Pricey NFL, NBA ownership stakes are pushing investors to smaller leagues and driving valuations higher

Trinity Rodman #2 of Washington Spirit evades Sarah Schupansky #11 of Gotham FC during the NWSL Championship 2025 final between Washington Spirit and NJ/NY Gotham FC at PayPal Park on November 22, 2025 in San Jose, California. Lyndsay Radnedge/isi Photos | Isi Photos | Getty Images A version of this article first appeared in the […]

Read More
Hershey says GLP-1s are driving higher gum and mint sales
Business

Hershey says GLP-1s are driving higher gum and mint sales

Packages of Ice Breakers spearmint mints Mints are displayed at a Costco Wholesale store on April 27, 2025 in San Diego, California. Kevin Carter | Getty Images Hershey is seeing higher sales for its mints and gum — thanks to the growing use of GLP-1 drugs. “We’ve also seen strong demand for gum and mints, […]

Read More
FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies
Business

FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies

The headquarters of the U.S. Food and Drug Administration in Silver Spring, Maryland, Nov. 4, 2009. Jason Reed | Reuters The ⁠Food and Drug ⁠Administration on Thursday proposed ​excluding the active ingredients in Novo Nordisk ‌and Eli Lilly‘s blockbuster obesity and diabetes medications from the ⁠list ⁠of drugs that outsourcing facilities can use for ​compounding […]

Read More